<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Brincidofovir (United States: Availability via FDA emergency investigational drug [e-IND] protocol): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Brincidofovir (United States: Availability via FDA emergency investigational drug [e-IND] protocol): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Brincidofovir (United States: Availability via FDA emergency investigational drug [e-IND] protocol): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="131802" href="/d/html/131802.html" rel="external">see "Brincidofovir (United States: Availability via FDA emergency investigational drug [e-IND] protocol): Drug information"</a> and <a class="drug drug_patient" data-topicid="131950" href="/d/html/131950.html" rel="external">see "Brincidofovir (United States: Availability via FDA emergency investigational drug [e-IND] protocol): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F55851999"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased risk for mortality when used for longer duration</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">An increased incidence of mortality was seen in brincidofovir-treated subjects compared to placebo-treated subjects in a 24-week clinical trial when brincidofovir was evaluated in another disease.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58220189"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tembexa</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F55852448"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent</span>;</li>
<li>
<span class="list-set-name">Antiviral Agent, Oral</span></li></ul></div>
<div class="block don drugH1Div" id="F55951391"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bad16888-a174-4afb-95b5-1cd5b0942d1f">Smallpox</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Smallpox (variola virus infection):</b> Oral suspension: Oral: 6 mg/kg once weekly for 2 doses (on day 1 and day 8).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F55951392"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bad16888-a174-4afb-95b5-1cd5b0942d1f">Smallpox</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Smallpox (variola virus infection):</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;10 kg: Oral suspension: Oral: 6 mg/kg once weekly for 2 doses (on day 1 and day 8).</p>
<p style="text-indent:-2em;margin-left:4em;">10 to &lt;48 kg: Oral suspension: Oral: 4 mg/kg once weekly for 2 doses (on day 1 and day 8).</p>
<p style="text-indent:-2em;margin-left:4em;">≥48 kg: Oral suspension or tablet: Oral: 200 mg once weekly for 2 doses (on day 1 and day 8).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F55951393"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney impairment: </b> No dosage adjustment needed for any degree of renal impairment (including end-stage renal disease).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> No dosage adjustment needed.</p></div>
<div class="block dohp drugH1Div" id="F55951397"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Hepatic impairment prior to initiation (baseline):</i></b> Infants, Children, and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild, moderate, or severe impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Hepatotoxicity during treatment:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">ALT persistently &gt;10 × ULN: Consider not administering second dose.</p>
<p style="text-indent:-2em;margin-left:4em;">ALT elevation with increased direct bilirubin, alkaline phosphatase, INR, or clinical signs of liver inflammation: Discontinue; do not administer second dose.</p></div>
<div class="block doa drugH1Div" id="F55949700"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="131802" href="/d/html/131802.html" rel="external">see "Brincidofovir (United States: Availability via FDA emergency investigational drug [e-IND] protocol): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97c777df-e720-4db8-8277-210aa1890f45">Nonvariola orthopoxvirus infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonvariola orthopoxvirus infection (eg, mpox [monkeypox]) (alternative agent) (off-label use): Note:</b> Reserve use for patients with or at risk for severe disease. Use in combination with tecovirimat; only use as monotherapy in patients who have a contraindication to tecovirimat use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36862595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36862595'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Limited data available: 200 mg once weekly for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35623380','lexi-content-ref-36862595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35623380','lexi-content-ref-36862595'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bad16888-a174-4afb-95b5-1cd5b0942d1f">Smallpox</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Smallpox: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">10 to &lt;48 kg: 4 mg/kg once weekly for 2 doses (days 1 and 8).</p>
<p style="text-indent:-2em;margin-left:4em;">≥48 kg: 200 mg once weekly for 2 doses (days 1 and 8).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F55949702"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F55949703"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment <b>prior to</b> treatment: </i>Mild, moderate, or severe impairment (Child-Pugh class A, B, or C): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment <b>during</b> treatment: </i>Consider discontinuation if ALT levels remain persistently &gt;10 × ULN. Do not administer second (final) dose on day 8 if ALT elevation is accompanied by clinical signs and symptoms of liver inflammation or increasing direct bilirubin, alkaline phosphatase, or INR.</p></div>
<div class="block arsc drugH1Div" id="F56180157"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">GI effects, including <b>abdominal pain</b>, <b>diarrhea</b>, <b>nausea</b>, and <b>vomiting</b>, sometimes requiring discontinuation of therapy, have been reported. GI effects can be severe; may resolve with discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; has been reported within the first 2 weeks of therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Increased serum alanine aminotransferase </b>(ALT),<b> increased serum aspartate aminotransferase </b>(AST), and <b>increased serum bilirubin</b> have been reported, including cases of concurrent increases in ALT and bilirubin. Severe hepatic events (eg, <b>hepatic sinusoidal obstruction syndrome</b>, <b>hepatitis (acute)</b>, <b>hyperbilirubinemia</b>, <b>liver steatosis</b>) have been reported rarely. Hepatotoxicity is generally reversible and treatment discontinuation may or may not be required depending on severity of hepatotoxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; has been reported within the first 2 weeks of therapy.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55862511"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (&lt;2%, including maculopapular rash and pruritic rash)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3%)<span class="lexi-table-link-container"> (<a aria-label="Abdominal Pain table link" class="lexi-table-link" data-table-id="lexi-content-abdominal-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abdominal-pain')">table 1</a>)</span><span class="table-link" style="display:none;">Abdominal Pain</span>, decreased appetite (&lt;2%), diarrhea (8%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 2</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, dysgeusia (&lt;2%), nausea (5%), vomiting (4%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 3</a>)</span><span class="table-link" style="display:none;">Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abdominal Pain" frame="border" id="lexi-content-abdominal-pain" rules="all">
<caption style="text-align:center;">
<b>Brincidofovir: Adverse Reaction: Abdominal Pain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Brincidofovir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Brincidofovir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">208</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Brincidofovir: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Brincidofovir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Brincidofovir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">208</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Brincidofovir: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Brincidofovir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Brincidofovir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">208</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (grades 2/3: 2% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Alanine Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-alanine-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-alanine-aminotransferase')">table 4</a>)</span><span class="table-link" style="display:none;">Increased Serum Alanine Aminotransferase</span>, increased serum aspartate aminotransferase (grades 2/3: 1% to 2%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Aspartate Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-aspartate-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-aspartate-aminotransferase')">table 5</a>)</span><span class="table-link" style="display:none;">Increased Serum Aspartate Aminotransferase</span>, increased serum bilirubin (grades 2/3: 1% to 3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Alanine Aminotransferase" frame="border" id="lexi-content-increased-serum-alanine-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Brincidofovir: Adverse Reaction: Increased Serum Alanine Aminotransferase</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Brincidofovir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Brincidofovir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;3 x ULN during the first 2 weeks of therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 2: 3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">208</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;3 to 5 x ULN</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3: 2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">208</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;5 to 20 x ULN</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Aspartate Aminotransferase" frame="border" id="lexi-content-increased-serum-aspartate-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Brincidofovir: Adverse Reaction: Increased Serum Aspartate Aminotransferase</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Brincidofovir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Brincidofovir)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 2: 2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">208</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;3 to 5 x ULN</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3: 1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">392</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">208</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;5 to 20 x ULN</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Myasthenia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic sinusoidal obstruction syndrome, hepatitis (acute), hyperbilirubinemia, liver steatosis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Dyspepsia, enteritis</p></div>
<div class="block coi drugH1Div" id="F55852005"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F55949683"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cidofovir: Do not coadminister with IV cidofovir; brincidofovir is a lipid-linked derivative of cidofovir that is intracellularly converted to cidofovir.</p></div>
<div class="block foc drugH1Div" id="F58220190"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tembexa: 10 mg/mL (65 mL) [contains sodium benzoate; lemon-lime flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tembexa: 100 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigo carm) aluminum lake]</p></div>
<div class="block geq drugH1Div" id="F58220188"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58262602"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Tembexa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Tembexa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F55949632"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Tembexa is not available for general public use. Supplies are owned by the US federal government. For treatment of smallpox, additional information is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Femergency-preparedness-and-response%2Fmcm-issues%2Fsmallpox-preparedness-and-response-updates-fda&amp;token=8CLjuLVtoKzpw11L8e6Vl4r8VO6PW1HhDjvHklB4Nw25MWP9MTX4LE3%2BYz87d852%2Br0x4uPaBlfrUCXa9AlI6xzmb3eFaiwzaWdD6Idaa95vytt3U5AFBJ6m4q2cJc22&amp;TOPIC_ID=131803" target="_blank">https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/smallpox-preparedness-and-response-updates-fda</a>. For treatment of mpox (monkeypox), a single-patient investigational new drug request may be submitted at https://erequest.navigator.reaganudall.org/#/home/presignup?emergency=monkeypox.</p></div>
<div class="block admp drugH1Div" id="F55951398"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Due to carcinogenic potential, avoid direct contact with broken or crushed tablets and oral suspension. If contact with skin or mucous membranes occur, wash thoroughly with soap and water, and rinse eyes thoroughly with water.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Administer on empty stomach or with low-fat meal (~400 calories with ~25% calories from fat). Swallow tablets whole; do not crush or divide.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Administer on empty stomach. Shake well. Use oral syringe to accurately measure prescribed dose. Discard unused portion after 2 doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Enteral feeding tube:</i> Flush enteral feeding tube with water prior to administration; may administer via tube using a catheter tip syringe, then refill syringe with 3 mL of water, shake, and administer to ensure all drug administered. Flush with water again following administration.</p></div>
<div class="block adm drugH1Div" id="F55949706"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Due to carcinogenic potential, avoid direct contact with broken or crushed tablets and oral suspension. If contact with skin or mucous membranes occurs, wash thoroughly with soap and water, and rinse eyes thoroughly with water.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Administer on an empty stomach or with a low-fat meal. Swallow tablet whole; do not crush or divide.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Administer on an empty stomach. Shake oral suspension before use. For patients who cannot swallow, oral suspension can be administered by enteral tube (following administration, refill the catheter-tip syringe with 3 mL of water, shake, and administer contents via tube to ensure full dose is administered); flush tube with water before and after enteral administration.</p></div>
<div class="block hazard drugH1Div" id="F55949686"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Brincidofovir may cause carcinogenicity, reproductive toxicity, and has a structural and/or toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F55949687"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F). Do not freeze oral suspension.</p></div>
<div class="block usep drugH1Div" id="F55852453"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Treatment of human smallpox disease caused by variola virus (FDA approved in all ages).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Not indicated for the treatment of diseases other than human smallpox disease. Treatment of smallpox disease has not been evaluated in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug's efficacy is not ethical.</p></div>
<div class="block mst drugH1Div" id="F55949630"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Brincidofovir may be confused with cidofovir.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55868965"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OATP1B1/1B3 (SLCO1B1/1B3); <b>Inhibits</b> MRP2</p></div>
<div class="block dri drugH1Div" id="F55868962"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cidofovir: Brincidofovir may enhance the adverse/toxic effect of Cidofovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Brincidofovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Brincidofovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Brincidofovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Brincidofovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Brincidofovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors: May increase the serum concentration of Brincidofovir. Management: Consider alternatives to OATP1B/1B3 inhibitors in patients treated with brincidofovir. If coadministration is required, administer OATP1B1/1B3 inhibitors at least 3 hours after brincidofovir and increase monitoring for brincidofovir adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Smallpox and Monkeypox Vaccine (Live): Brincidofovir may diminish the therapeutic effect of Smallpox and Monkeypox Vaccine (Live). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Smallpox Vaccine Live: Brincidofovir may diminish the therapeutic effect of Smallpox Vaccine Live. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F55949685"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases the brincidofovir oral tablet AUC and C<sub>max</sub> by 31% and 49%, respectively. The effect of food on brincidofovir oral suspension has not been studied. Management: Take brincidofovir tablets on an empty stomach or with a low-fat meal. Take brincidofovir oral suspension on an empty stomach.</p></div>
<div class="block dic drugH1Div" id="F55949705"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Take on an empty stomach or with a low-fat meal (~400 calories, with ~25% of calories from fat).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Take on an empty stomach.</p></div>
<div class="block rep_considerations drugH1Div" id="F55949634"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy testing is recommended prior to use in patients who may become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who may become pregnant should use effective contraception during therapy and for at least 2 months after the last brincidofovir dose. Patients with partners who may become pregnant should use condoms during therapy and for at least 4 months after the last dose of brincidofovir.</p></div>
<div class="block pri drugH1Div" id="F55949635"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Maternal toxicity and adverse pregnancy outcomes were observed in animal reproduction studies with doses less than the expected human exposure. Based on data from animal reproduction studies, in utero exposure to brincidofovir may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Smallpox infection during pregnancy is associated with adverse events. Contracting smallpox while pregnant increases the risk of severe maternal disease (including hemorrhagic smallpox) and death; the fatality rate in unvaccinated pregnant patients can be up to 70% (CDC [Petersen 2015]).</p>
<p style="text-indent:0em;margin-top:2em;">Alternative therapy to treat smallpox infection in pregnant patients should be used if available. Brincidofovir is not recommended as an alternative therapy to treat patients with mpox (monkeypox) during the first trimester (CDC 2022a).</p></div>
<div class="block mopp drugH1Div" id="F55951399"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">Liver function tests before treatment and during treatment as clinically appropriate; bilirubin and INR as clinically appropriate (ie, patients with ALT elevation); pregnancy test (in patients who can become pregnant); monitor for diarrhea and dehydration.</p></div>
<div class="block pha drugH1Div" id="F55949688"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Brincidofovir is a lipid conjugate that is converted intracellularly to cidofovir, which is subsequently phosphorylated to an active metabolite, cidofovir diphosphate. Cidofovir diphosphate selectively inhibits orthopoxvirus DNA polymerase-mediated viral DNA synthesis. Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis</p></div>
<div class="block phk drugH1Div" id="F55949689"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Administration of oral tablet with a low-fat meal resulted in decreases in AUC (31%) and C<sub>max</sub> (49%) relative to administration under fasted conditions. The effect of food on oral suspension absorption was not studied.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 1,230 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99.9 % bound to human plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hydrolyzed to cidofovir, then phosphorylated to form cidofovir diphosphate (active metabolite).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tablet: 13.4%; oral suspension: 16.8%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Brincidofovir: 19.3 hours; cidofovir diphosphate (active metabolite): 113 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Brincidofovir: 3 hours (range: 2 to 8 hours); cidofovir diphosphate (active metabolite): 47 hours (range: 23 to 311 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (51%, as metabolites); feces (40%, as metabolites).</p></div>
<div class="block phksp drugH1Div" id="F55951389"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Recommended pediatric dosing regimen is expected to result in similar exposures to adults, based on population pharmacokinetic modeling and simulation.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35623380">
<a name="35623380"></a>Adler H, Gould S, Hine P, et al; NHS England High Consequence Infectious Diseases (Airborne) Network. Clinical features and management of human monkeypox: a retrospective observational study in the UK. <i>Lancet Infect Dis</i>. 2022;22(8):1153-1162. doi:10.1016/S1473-3099(22)00228-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brincidofovir-united-states-availability-via-fda-emergency-investigational-drug-e-ind-protocol-pediatric-drug-information/abstract-text/35623380/pubmed" id="35623380" target="_blank">35623380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Clinical considerations for monkeypox in people who are pregnant or breastfeeding. <a href="https://www.cdc.gov/poxvirus/monkeypox/clinicians/pregnancy.html" target="_blank">https://www.cdc.gov/poxvirus/monkeypox/clinicians/pregnancy.html</a>. Updated July 18, 2022a. Accessed July 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Interim clinical guidance for the treatment of monkeypox. <a href="https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html" target="_blank">https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html</a>. Updated October 31, 2022b. Accessed November 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25695372">
<a name="25695372"></a>Petersen BW, Damon IK, Pertowski CA, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. <i>MMWR Recomm Rep</i>. 2015;64(RR-2):1-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brincidofovir-united-states-availability-via-fda-emergency-investigational-drug-e-ind-protocol-pediatric-drug-information/abstract-text/25695372/pubmed" id="25695372" target="_blank">25695372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36862595">
<a name="36862595"></a>Rao AK, Schrodt CA, Minhaj FS, et al. Interim clinical treatment considerations for severe manifestations of Mpox - United States, February 2023. <i>MMWR Morb Mortal Wkly Rep.</i> 2023;72(9):232-243. doi:10.15585/mmwr.mm7209a4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brincidofovir-united-states-availability-via-fda-emergency-investigational-drug-e-ind-protocol-pediatric-drug-information/abstract-text/36862595/pubmed" id="36862595" target="_blank">36862595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tembexa.1">
<a name="Tembexa.1"></a>Tembexa (brincidofovir) [prescribing information]. Whippany, NJ: Cambrex Whippany Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed June 7, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 131803 Version 37.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
